Literature DB >> 16242849

Galantamine increases excitability of CA1 hippocampal pyramidal neurons.

M M Oh1, W W Wu, J M Power, J F Disterhoft.   

Abstract

Galantamine is a third generation cholinesterase inhibitor and an allosteric potentiating ligand of nicotinic acetylcholine receptors. It enhances learning in aging rabbits and alleviates cognitive deficits observed in patients with Alzheimer's disease. We examined galantamine's effect on CA1 neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Galantamine (10-200 microM) dose-dependently reduced the postburst afterhyperpolarization and the spike-frequency accommodation of CA1 neurons from both young and aging animals. These reductions were partially, but significantly, reversed by the addition of the muscarinic receptor antagonist, atropine (1 microM), to the perfusate. In contrast, the nicotinic acetylcholine receptor antagonist, alpha-bungarotoxin (10 nM), had no effect; i.e. alpha-bungarotoxin did not reverse the afterhyperpolarization and accommodation reductions. The allosteric potentiating ligand effect was examined by stimulating the Schaffer collateral and measuring the excitatory postsynaptic potentials for 30 min during bath application of galantamine. Galantamine (200 microM) significantly enhanced the excitatory postsynaptic potential amplitude and area over time. These effects were blocked by 10 nM alpha-bungarotoxin, supporting a role for galantamine as an allosteric potentiating ligand. We did not observe a facilitation of the excitatory postsynaptic potentials with 1 microM galantamine. However, when the excitatory postsynaptic potential was pharmacologically isolated by adding 10 microM gabazine (GABA(A) receptor antagonist) to the perfusate, 1 microM galantamine potentiated the subthreshold excitatory postsynaptic potentials into action potentials. We propose that the learning enhancement observed in aging animals and the alleviation of cognitive deficits associated with Alzheimer's disease after galantamine treatment may in part be due to the enhanced function of both nicotinic and muscarinic excitatory transmission on hippocampal pyramidal neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242849     DOI: 10.1016/j.neuroscience.2005.08.063

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

Review 1.  The impact of hippocampal lesions on trace-eyeblink conditioning and forebrain-cerebellar interactions.

Authors:  Craig Weiss; John F Disterhoft
Journal:  Behav Neurosci       Date:  2015-08       Impact factor: 1.912

2.  Increasing SK2 channel activity impairs associative learning.

Authors:  Bridget M McKay; M Matthew Oh; Roberto Galvez; Jeffrey Burgdorf; Roger A Kroes; Craig Weiss; John P Adelman; Joseph R Moskal; John F Disterhoft
Journal:  J Neurophysiol       Date:  2012-05-02       Impact factor: 2.714

Review 3.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  Learning and aging affect neuronal excitability and learning.

Authors:  M Matthew Oh; John F Disterhoft
Journal:  Neurobiol Learn Mem       Date:  2019-11-28       Impact factor: 2.877

Review 5.  Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.

Authors:  Trevor W Stone
Journal:  J Neurochem       Date:  2019-11-24       Impact factor: 5.372

6.  Pharmacological dissociation of novelty responses in the human brain.

Authors:  Nico Bunzeck; Marc Guitart-Masip; Raymond J Dolan; Emrah Duzel
Journal:  Cereb Cortex       Date:  2013-01-10       Impact factor: 5.357

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.